Ganitumab Revived for Aggressive Breast Cancer Therapy

A recent groundbreaking study led by Lund University in Sweden has resurfaced a previously shelved drug, ganitumab, as a potential treatment for aggressive breast cancer. This discovery offers renewed hope that this targeted cancer therapy could once again be developed for clinical use, particularly benefiting patients who previously had no options.

Context and Background

Ganitumab had initially shown promising results against breast cancer during animal trials, but its clinical application faced challenges. Despite substantial investments—both in time and finances—researchers were unable to determine which specific breast cancer patients could benefit from this treatment. This gap in knowledge hindered the drug's progression to broader clinical availability.

Challenges in Identifying Beneficial Indicators

The core challenge in deploying ganitumab is the lack of clear diagnostic markers that could indicate which patients would respond positively to the treatment. Ganitumab operates by blocking the insulin-like growth factor I receptor (IGF-IR) on tumor cells, a receptor linked to tumor growth and metastasis.

Dr. Michael Pollak, a professor at McGill University and co-author of the new study, expressed disappointment about the previous findings. He remarked:

“We saw clear results in preclinical studies, but when examining entire patient cohorts, it became challenging to make definitive conclusions.”

Novel Insights from New Research

In collaboration with data from the I-SPY2 trial in North America, researchers in Sweden utilized bioinformatics to revisit the genetic and molecular data of tumors. Christopher Godina, the first author of the study and a post-doctoral researcher at Lund University, spearheaded this initiative by mapping gene expressions in breast tumors. His analysis compared these expressions to clinical outcomes.

The unexpected revelation was the identification of a novel biomarker: IGFBP7. This biomarker allows researchers to predict which patients might benefit from ganitumab treatment. This was surprising because it was previously believed that tumors with higher levels of IGFBP7 were more susceptible to the drug.

Findings from the IGFBP7 Analysis

The analysis of tumor samples revealed significant results:

These findings suggest that approximately 25% of all patients with aggressive breast cancer could significantly benefit from ganitumab treatment, potentially marking a pivotal advancement for patients who previously had limited options.

Implications for Future Cancer Treatments

Moreover, researchers suggest that this biomarker's implications may extend beyond breast cancer, opening doors for potential applications in treating other malignancies. Professor Helena Jernström of Lund University emphasized the significance of these findings by stating:

“A quarter of all patients with aggressive breast cancer may now benefit from this treatment. This discovery could represent a breakthrough after numerous unsuccessful attempts to delineate patient responses.”

The study's success highlights the necessity for transparency and collaborative data sharing in scientific research. It emphasizes that without the availability of prior research data, solving complex problems such as these could prove to be insurmountable.

Conclusion

The revival of ganitumab represents a significant step forward in targeted breast cancer therapies. The identification of IGFBP7 as a novel biomarker suggests new directions for treatment stratification, potentially leading to personalized cancer care that optimizes therapeutic efficacy and minimizes unnecessary exposure for patients unlikely to benefit from the drug.

References

Godina, C., et al. (2024). Targeting IGF-IR improves neoadjuvant chemotherapy efficacy in breast cancers with low IGFBP7 expression. npj Precision Oncology. DOI: 10.1038/s41698-024-00712-9.

Lifespan.io